CRISPR Therapeutics sets sights on gene-editing cures for disease

Key PointsVertex Pharmaceuticals received FDA approval for Casgevy for the treatment of sickle cell disease (SCD) utilizing CRISPR/Cas9 gene-editing technology.CRISPR Therapeutics partnered with Vertex in the development of Casgevy and aims to use the technology to treat more hereditary diseases.CRSP shares fell 20% following the FDA announcement and downgrade by Cowen to Underperform with a $30 price target.5 stocks we like better than CRISPR TherapeuticsOn Dec. 8, 2023, Vertex Pharmaceuticals Inc. NASDAQ: ...